There Is an Urgent Need for More Efficacious High-Grade Glioma Treatments, but Will the Current Therapeutic Pipeline Suffice?Decision Resources
December 1, 2011
More CNS/Neurology reports by Decision Resources
Niche Markets and Rare Diseases: Amyotrophic Lateral Sclerosis by Decision Resources
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neurone disease (MND), is a degenerative disorder of the nervous system ...
Migraine by Decision Resources
All the currently available triptan products, which constituted 70% of the migraine major-market sales in 2011, will face generic competition during our forecast ...
ChartTrends®: Multiple Sclerosis (EU) 2012 by Decision Resources
BioTrends Research Group is pleased to announce the continuation of ChartTrends®: Multiple Sclerosis in the EU in 2012. In this report, patient level data are ...
How Have Zyprexa’s Patent Expiry, the Launch of Novel Atypical Antipsychotics, and Payer Decisions Reshaped U.S. Physician Behaviors in the Major Psychiatry Markets? by Decision ResourcesSee all reports like this >>
This U.S. Physician and Payer Forum explores payer and physician dynamics that affect prescribing practices for atypical antipsychotics for schizophrenia, bipolar disorder, ...
We can help you find what you need. Call us or write us:
Need help in your search?